YAP is a key oncogenic driver that has long been considered undruggable. Here, the authors present the development of a nanobody-based bioPROTAC that efficiently degrades endogenous YAP, demonstrating potent anticancer activity and providing a promising therapeutic strategy for YAP-dependent tumors.
- Runhua Zhou
- Huifang Wang
- Yi-Lei Li
